A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer

BACKGROUND: Adjuvant intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) is considered as the first-line agent in patients with high-risk nonmuscle invasive bladder cancer (NMIBC) after surgery. There are no data in India where there is a high prevalence of tubercle bacillus and inherent...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshua, Julie Mariam, Vijayan, Meenu, Pooleri, Ginil Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402057/
https://www.ncbi.nlm.nih.gov/pubmed/30858894
http://dx.doi.org/10.1177/1756287219833056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402057/
https://www.ncbi.nlm.nih.gov/pubmed/30858894
http://dx.doi.org/10.1177/1756287219833056

Ejemplares similares